BETter Insight into PRC2-mutated T-ALL

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2021 Nov 11

PMID 34762130

Authors

Charles E de Bock

Jan Cools

Affiliations

Soon will be listed here.

References

Kim J, Lee Y, Lu X, Song B, Fong K, Cao Q . Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Rep. 2018; 25(10):2808-2820.e4. PMC: 6342284. DOI: 10.1016/j.celrep.2018.11.035. View

Gilan O, Rioja I, Knezevic K, Bell M, Yeung M, Harker N . Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020; 368(6489):387-394. PMC: 7610820. DOI: 10.1126/science.aaz8455. View

de Bock C, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O . HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018; 8(5):616-631. DOI: 10.1158/2159-8290.CD-17-0583. View

Andrieu G, Kohn M, Simonin M, Smith C, Cieslak A, Dourthe M . PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. Blood. 2021; 138(19):1855-1869. PMC: 9642784. DOI: 10.1182/blood.2020010081. View

Laugesen A, Helin K . Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell. 2014; 14(6):735-51. DOI: 10.1016/j.stem.2014.05.006. View

Morin R, Johnson N, Severson T, Mungall A, An J, Goya R . Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010; 42(2):181-5. PMC: 2850970. DOI: 10.1038/ng.518. View

Broux M, Prieto C, Demeyer S, Vanden Bempt M, Alberti-Servera L, Lodewijckx I . Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. Blood. 2019; 134(16):1323-1336. PMC: 6888143. DOI: 10.1182/blood.2019000015. View

Ma A, Stratikopoulos E, Park K, Wei J, Martin T, Yang X . Discovery of a first-in-class EZH2 selective degrader. Nat Chem Biol. 2019; 16(2):214-222. PMC: 6982609. DOI: 10.1038/s41589-019-0421-4. View

Oshima K, Zhao J, Perez-Duran P, Brown J, Patino-Galindo J, Chu T . Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat Cancer. 2021; 1(11):1113-1127. PMC: 8011577. DOI: 10.1038/s43018-020-00124-1. View

10.

Yosifov D, Wolf C, Stilgenbauer S, Mertens D . From Biology to Therapy: The CLL Success Story. Hemasphere. 2019; 3(2):e175. PMC: 6746030. DOI: 10.1097/HS9.0000000000000175. View